Clinical efficacy and safety of ulinastatin combined with octreotide in the treatment of acute pancreatitis
10.3760/cma.j.issn.1008-6706.2017.20.029
- VernacularTitle:乌司他丁联合奥曲肽治疗急性胰腺炎的临床疗效分析
- Author:
Shengai ZHAO
;
Fuyin GAO
;
Jiandong NAN
- Keywords:
Pancreatitis;
Ulinastatin;
Octreotide
- From:
Chinese Journal of Primary Medicine and Pharmacy
2017;24(20):3149-3152
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy and safety of ulinastatin combined with octreotide in the treatment of acute pancreatitis.Methods The clinical data of 50 patients with acute pancreatitis were retrospectively analyzed.According to different methods of treatment,they were divided into two groups.25 patients in the control group were treated with octreotide alone,while 25 patients in the observation group were treated with ulinastatin combined with octreotide.The clinical treatment effect and the incidence of complications were compared between the two groups.Results The total effective rate of the observation group was 96.00％,which was significantly higher than 80.00％ of the control group,the difference was statistically significant (x2 =9.64,P ＜ 0.05).The recovery time of abdominal pain and distension,recovery time of serum amylase,recovery time of urine amylase and the average hospitalization time of the observation group were (4.83 ± 1.21) d,(3.49 ± 1.08) d,(4.26 ± 1.17) d,(15.24 ± 3.16) d,which were significantly shorter than those of the control group (t =6.56,7.30,6.82,7.11,all P ＜ 0.05).The incidence rate of complications of the observation group was 12.00％,which was significantly lower than 36.00％ of the control group,the difference was statistically significant (x2 =8.56,P ＜ 0.05).Conclusion Ulinastatin combined with octreotide has significant effect in the treatment of acute pancreatitis,which can improve the symptoms and promote the early recovery,and the incidence rate of complication is low and the safety is high,which is worthy of clinical application and promotion.
